On November 11, 2022 Aucentra Therapeutics reported the appointment of Dr David Fuller as ‘Chief Medical Officer’ and a member of the executive management team commencing 16 November 2022 (Press release, Aucentra, NOV 11, 2022, View Source [SID1234623850]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Fuller will lead the company’s Australia and global clinical development at a crucial time of significant growth. His extensive experience and background as a biopharmaceutical executive and physician will pave the way with Aucentra Therapeutics lead candidate Auceliciclib Phase II/III clinical trial and progress the pipeline of clinical and pre-clinical drug programs.

During his career, Dr Fuller has led successful major market drug approvals including Moraxen (UK), Busulfex (US Paediatrics and EU Adult indications), Xyrem (US) and Renagel (EU). He has also designed and executed multiple Phase I, II and III studies (US, EU, Asia) for both orphan and non-orphan drug products.

Dr Fuller brings with him international prowess and extensive knowledge of research development & commercialisation of novel pharmaceuticals. His 30 years’ experience spans large, mid, and small cap companies including pre-clinical and clinical development, medical and regulatory affairs, and commercialisation.